文献速递疼痛医学术前评估与围术期医学

糖尿病多部位与特定部位慢性疼痛、镇痛药使用、代谢蛋白质组特征与新发慢性肾病的关系

Association between Multisite and Site-specific Chronic Pain, Analgesic Use, Metabolic-Proteomic Profile, and Incident Chronic Kidney Disease in Diabetes.
PubMed 文献 · Anesthesiology · 2025-11-04

该研究基于英国生物银行20208例糖尿病患者,随访13.2年发现慢性疼痛与慢性肾病风险升高18%相关,多部位疼痛呈剂量依赖性,阿片类药物使用与风险升高22%相关,而布洛芬和对乙酰氨基酚无显著关联。多组学分析发现嗜铬粒蛋白A升高、糖蛋白乙酰基升高及omega-3与总脂肪酸比值降低三个生物标志物,蛋白网络分析显示TNF和EGFR为核心节点。

要点

  • 糖尿病患者慢性疼痛与新发慢性肾病风险升高18%相关(调整HR 1.18,95%CI 1.08-1.28)。
  • 多部位疼痛与慢性肾病风险呈剂量依赖性关联(每增加一个部位调整HR 1.08,95%CI 1.05-1.12)。
  • 慢性疼痛患者中阿片类药物使用与慢性肾病风险升高22%相关,布洛芬和对乙酰氨基酚无显著关联。

核心结论

  • 糖尿病多部位慢性疼痛和阿片类药物使用与新发慢性肾病风险升高相关,代谢蛋白质组特征支持该关联,提示糖尿病护理中需关注肾脏安全的疼痛管理。

研究设计与样本

  • 基于英国生物银行20208例糖尿病且慢性疼痛部位信息完整的参与者,采用多变量Cox回归评估慢性疼痛及镇痛药使用与新发慢性肾病的关联,并整合248种代谢物和2911种蛋白质的多组学数据探索生物通路。

主要发现

  • 中位随访13.2年期间记录2589例新发慢性肾病。
  • 慢性疼痛与慢性肾病风险升高18%相关(调整HR 1.18,95%CI 1.08-1.28)。
  • 特定部位分析显示颈部/肩部、背部、髋部、膝部和胃/腹部疼痛与慢性肾病风险显著相关,头痛和面部疼痛无显著关联。
  • 多部位疼痛与慢性肾病风险呈剂量依赖性关系(每增加一个部位:调整HR 1.08,95%CI 1.05-1.12)。
  • 慢性疼痛参与者中阿片类药物使用与慢性肾病风险显著正相关(调整HR 1.22,95%CI 1.06-1.40),布洛芬和对乙酰氨基酚无显著关联。

关键数值与推荐

  • 慢性疼痛:调整HR 1.18,95%CI 1.08-1.28,对象为糖尿病患者。
  • 多部位疼痛每增加一个部位:调整HR 1.08,95%CI 1.05-1.12,对象为糖尿病患者。
  • 阿片类药物使用:调整HR 1.22,95%CI 1.06-1.40,对象为慢性疼痛的糖尿病患者。
  • 多组学分析识别三个一致失调的生物标志物:嗜铬粒蛋白A升高、糖蛋白乙酰基升高、omega-3与总脂肪酸比值降低,见于所有五个显著疼痛部位。
  • 蛋白网络分析显示TNF和EGFR为慢性疼痛-慢性肾病风险关联的中心节点。

临床怎么用

  • 对糖尿病合并慢性疼痛患者应评估慢性肾病风险,尤其多部位疼痛者。
  • 疼痛管理中选择镇痛药时需考虑肾脏安全性,阿片类药物使用与慢性肾病风险升高相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although chronic pain is highly prevalent among individuals with diabetes, its relationship with the risk of developing chronic kidney disease (CKD) in this population remains poorly understood. The authors aimed to explore the associations between multisite chronic pain and analgesic use with CKD risk in people with diabetes, and to further characterize the underlying metabolic and proteomic signatures. METHODS: The authors analyzed data from 20,208 UK Biobank participants with diabetes and complete chronic pain site information (headache, facial, neck/shoulder, back, stomach/abdominal, hip, knee). Using multivariable Cox regression models, they evaluated the prospective associations between chronic pain (both site specific and multisite), analgesic use (ibuprofen, paracetamol, opioid), and incident CKD risk. Multiomics data (248 metabolites, 2,911 proteins) were integrated to explore biological pathways. RESULTS: During a median follow-up of 13.2 yr, 2,589 incident CKD cases were documented. Chronic pain was associated with an 18% higher CKD risk (adjusted hazard ratio [HR], 1.18; 95% CI, 1.08 to 1.28). Site-specific analysis identified significant associations between CKD risk and pain in neck/shoulder, back, hip, knee, and stomach/abdominal regions, while headache and facial pain showed no significant associations. Multisite pain exhibited a dose-dependent relationship with CKD risk (per additional site: adjusted HR, 1.08; 95% CI, 1.05 to 1.12). Among participants with chronic pain, opioid use showed significant positive associations with CKD risk (adjusted HR, 1.22; 95% CI, 1.06 to 1.40), whereas ibuprofen and paracetamol demonstrated no significant associations. Multiomics secondary analysis identified three consistently dysregulated biomarkers across all five significant pain sites: elevated chromogranin-A, increased glycoprotein acetyls, and reduced omega-3 to total fatty acids ratio. Protein network analysis revealed tumor necrosis factor (TNF) and epidermal growth factor receptor (EGFR) as central nodes in the observed chronic pain-CKD risk associations. CONCLUSIONS: Multisite chronic pain and opioid use are associated with elevated CKD risk in diabetes, supported by metabolomic/proteomic signatures. These findings highlight the need for renal-conscious pain management in diabetes care.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Yang S, Zhang Y, Huang Y, et al. Association between Multisite and Site-specific Chronic Pain, Analgesic Use, Metabolic-Proteomic Profile, and Incident Chronic Kidney Disease in Diabetes. Anesthesiology. 2025. PMID: 41187022. doi:10.1097/ALN.0000000000005829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。